Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients. 1989

J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
CNRS UA 1179-INSERM U 172, Laboratoire de Biochimie, Faculté de Médecine Nord, Marseille, France.

Human sera were tested for the presence of anti-nef antibodies by radioimmunoassay (RIA), with recombinant radiolabelled nef expressed in E. coli. Of the 300 HIV-positive sera tested by RIA, 70 +/- 5.3% were found to be anti-nef positive. Anti-nef antibodies bound to nef with a high affinity (K 0.5 = 2.2 x 10(-9) M). In 31 of the sera, the specificity of anti-nef antibodies was further analysed by enzyme-linked immunosorbent assay (ELISA) with large synthetic peptides ranging from 31 to 66 amino acid residues and spanning the total sequence of nef from HIV-1. The results obtained showed that the immunodominant antigenic sites of nef were located close to the N- and C-terminal regions of the molecule.

UI MeSH Term Description Entries
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005809 Genes, Regulator Genes which regulate or circumscribe the activity of other genes; specifically, genes which code for PROTEINS or RNAs which have GENE EXPRESSION REGULATION functions. Gene, Regulator,Regulator Gene,Regulator Genes,Regulatory Genes,Gene, Regulatory,Genes, Regulatory,Regulatory Gene
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
June 1989, AIDS research and human retroviruses,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
November 2012, Protein and peptide letters,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
May 1992, AIDS (London, England),
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
March 2018, Journal of immunological methods,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
April 1986, Journal of immunological methods,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
August 2005, Cellular & molecular immunology,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
January 1989, Viral immunology,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
January 1992, Archives of virology,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
January 2003, Revista Argentina de microbiologia,
J M Sabatier, and B Clerget-Raslain, and G Fontan, and E Fenouillet, and H Rochat, and C Granier, and J C Gluckman, and J Van Rietschoten, and L Montagnier, and E Bahraoui
September 2009, Biochimie,
Copied contents to your clipboard!